Your browser doesn't support javascript.
loading
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.
Handelsman, Yehuda; Butler, Javed; Bakris, George L; DeFronzo, Ralph A; Fonarow, Gregg C; Green, Jennifer B; Grunberger, George; Januzzi, James L; Klein, Samuel; Kushner, Pamela R; McGuire, Darren K; Michos, Erin D; Morales, Javier; Pratley, Richard E; Weir, Matthew R; Wright, Eugene; Fonseca, Vivian A.
Afiliación
  • Handelsman Y; Metabolic Institute of America, Tarzana, CA, USA. Electronic address: yhandelsman@gmail.com.
  • Butler J; Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA; University of Mississippi Medical Center, Jackson, MS, USA.
  • Bakris GL; American Heart Association Comprehensive Hypertension Center, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
  • DeFronzo RA; University of Texas Health Science Center at San Antonio, Texas Diabetes Institute, San Antonio, TX, USA.
  • Fonarow GC; Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center, UCLA Preventative Cardiology Program, UCLA Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Green JB; Division of Endocrinology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
  • Grunberger G; Grunberger Diabetes Institute, Internal Medicine and Molecular Medicine & Genetics, Wayne State University School of Medicine, Department of Internal Medicine, Oakland University William Beaumont School of Medicine, Bloomfield Hills, MI, USA; Department of Internal Medicine, First Faculty of Med
  • Januzzi JL; Cardiology Division, Harvard Medical School, Massachusetts General Hospital, Cardiometabolic Trials, Baim Institute, Boston, MA, USA.
  • Klein S; Washington University School of Medicine, Saint Louis, MO, USA; Sansum Diabetes Research Institute, Santa Barbara, CA, USA.
  • Kushner PR; University of California Medical Center, Kushner Wellness Center, Long Beach, CA, USA.
  • McGuire DK; University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, TX, USA.
  • Michos ED; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Morales J; Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; Advanced Internal Medicine Group, PC, East Hills, NY, USA.
  • Pratley RE; AdventHealth Translational Research Institute, Orlando, FL, USA.
  • Weir MR; Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Wright E; Department of Medicine, Duke University Medical Center, Durham, NC, USA.
  • Fonseca VA; Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA, USA.
J Diabetes Complications ; 37(2): 108389, 2023 02.
Article en En | MEDLINE | ID: mdl-36669322
Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too often, the risk factors for these disorders are not addressed promptly in clinical practice, leading to irreversible pathologic progression. To address this gap, we convened a Task Force of experts in cardiology, nephrology, endocrinology, and primary care to develop recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. The recommendations include screening and diagnosis, early interventions with lifestyle, and when and how to implement medical therapies. These recommendations are organized into primary and secondary prevention along the continuum from obesity through the metabolic syndrome, prediabetes, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, chronic kidney disease (CKD), and heart failure (HF). The goal of early and intensive intervention is primary prevention of comorbidities or secondary prevention to decrease further worsening of disease and reduce morbidity and mortality. These efforts will reduce clinical inertia and may improve patients' well-being and adherence.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 11_delivery_arrangements / 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_arterial_hypertension / 6_cardiovascular_diseases / 6_diabetes / 6_endocrine_disorders Asunto principal: Enfermedades Cardiovasculares / Diabetes Mellitus / Hipertensión Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Diabetes Complications Asunto de la revista: ENDOCRINOLOGIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 11_delivery_arrangements / 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_arterial_hypertension / 6_cardiovascular_diseases / 6_diabetes / 6_endocrine_disorders Asunto principal: Enfermedades Cardiovasculares / Diabetes Mellitus / Hipertensión Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Diabetes Complications Asunto de la revista: ENDOCRINOLOGIA Año: 2023 Tipo del documento: Article
...